The UK government has entered into a contract with Abingdon Health, on behalf of the UK-Rapid Test Consortium (UK-RTC), for the supply of the AbC-19TM Rapid Antibody tests, and has placed its first order for one million COVID-19 rapid antibody tests.
The AbC-19 Rapid Antibody Test, has already received the CE marking, uses a small drop of blood from a finger-prick and shows results in 20 minutes, without the need to go to a specialised laboratory. It can be administered by healthcare professionals, such as doctors, nurses, pharmacists and healthcare workers, at the point-of-care.
The test will make it possible to build a swift and clear picture of how the virus has spread throughout the UK population. It will also be able to help establish the effectiveness of any vaccine which provides protection by creating new antibodies.
Abingdon Health CEO Chris Yates said: “Our test will help give a picture of how many people in the UK have antibodies. This will be a crucial part of the understanding of immunity to COVID-19.
“Mass testing will also help understand what the longevity of immunity is and, in time, help assess the efficiency of any vaccine on the market. In this respect, high-quality mass antibody testing has never been more important, and it will be critical for future public health responses.
“The UK government order of the first one million tests is an endorsement of this UK designed, developed and manufactured high-quality rapid diagnostic test. It is a triumph of British business and a breakthrough for UK life sciences.
“We have ramped up production since the start of August and will be ready to deliver the first tests to the Government by early October. I would like to express my thanks to all my Abingdon Health colleagues for their tremendous support and hard work in achieving this milestone.”
To read more, please click here.